Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)
Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will assess how effective upadacitinib is in treating UC.
Upadacitinib (RINVOQ) is an approved drug for treating UC. Approximately 400 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in Germany, Austria and Switzerland.
Upadacitinib will be administered in accordance with the terms of the local marketing authorization, and treatment of participants will be determined solely by the investigator. Participants in the study will be followed for up to 2 years.
There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and only data which are routinely collected during a regular visit will be utilized for this study.
Inclusion Criteria:
Exclusion Criteria:
Brandenburg an der Havel, Brandenburg 14776, Germany
Tostedt, Free and Hanseatic City of Hamburg 21255, Germany
Kassel, Hesse 34117, Germany
Coesfeld, North Rhine-Westphalia 48653, Germany
Herne, North Rhine-Westphalia 44623, Germany
Minden, North Rhine-Westphalia 32423, Germany
Ludwigshafen am Rhein, Rhineland-Palatinate 67067, Germany
Kiel, Schleswig-Holstein 24146, Germany
Lübeck, Schleswig-Holstein 23538, Germany
Erfurt, Thuringia 99084, Germany
Berlin, 12559, Germany
Berlin-Zehlendorf, 14163, Germany
Blaubeuren Abbey, 89143, Germany
Stuttgart, 70435, Germany